Overview

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).
Phase:
Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.